The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
May 14, 2025
Loading feed metadata...
Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet
Sign up